You are here

[Evaluation of Morpholino antisense oligos' role on BCR-ABL gene silencing in the K562 cell line]

Authors: 
Haririan M, Kaviani S, Soleimani M, Noruzinia M, Abroun S, Rasi Ghaemi S, Delalat B
Citation: 
Yakhteh Medical Journal. 2010;12(2):241-248
Abstract: 
Objective: Chronic myeloid leukemia (CML) develops when a hematopoietic stem cell acquires the BCR/ABL fusion gene. This causes these transformed hematopoietic cells to have a greater than normal proliferation rate. Scientists attempt to improve the CML treatment process by silencing the BCR/ABL oncogene. In this work, we used morpholino antisense oligos to silence the BCR/ABL oncogene. Materials and Methods: In this study, the K562 was used as a BCR/ABL fusion-gene positive cell line and the Jurkat cell line as a control. We explored the inhibiting capacity of morpholino antisense oligos in the the expression of the BCR/ABL oncogene and studied their p210 BCR/ABL suppression, inhibition of cell proliferation and stimulation of apoptosis in the K562 cells after 24 and 48 hours. Endo-Porter was used for delivery of morpholino antisense oligos into cell cytosols. Meanwhile, flow cytometric analysis was performed in order to determine the appropriate concentration of morpholino antisense oligos. Results: Prolonged exposure of the K562 cell line to the morpholino antisense oligos targeted against the BCR-ABL gene showed proliferation inhibition as its main feature. After western blotting, we found that complete silencing of BCR/ABL was achieved, but flow cytometric analysis showed no broad apoptosis. Conclusion: The results indicate that the Morpholino antisense oligo is able to inhibit p210 BCR/ABL; however, it cannot induce broad apoptosis due to co-silencing of BCR.
Organism or Cell Type: 
cell culture: K562, Jurkat
Delivery Method: 
Endo-Porter